Leprosy: Challenges and Control Measures in India

Leprosy, also known as Hansen’s disease, remains one of the oldest diseases known to humanity. Despite significant medical advances over the past century, this chronic infectious disease continues to affect communities in India, making it a critical public health concern. Understanding leprosy-its causes, clinical presentation, and the comprehensive efforts to control it-is essential for nursing professionals who play a pivotal role in early detection, treatment, and community education.

Understanding leprosy: the causative agent and transmission 🔗

Leprosy is caused by Mycobacterium leprae, a slow-growing, acid-fast bacillus that primarily affects the skin and peripheral nerves. The bacterium has an extraordinarily long generation time of approximately 12 to 13 days, which explains why the disease progresses slowly and symptoms may take years to appear. The incubation period can range from one year to as long as 20 years after initial exposure.

The bacteria are transmitted through respiratory droplets expelled when an infected, untreated person coughs or sneezes. However, it’s important to emphasize that leprosy is not highly contagious. Prolonged, close contact over many months is typically required for transmission. According to the World Health Organization, casual contact such as shaking hands, hugging, sharing meals, or sitting next to an affected person does not spread the disease. Once treatment begins, the patient stops transmitting the bacteria almost immediately.

Clinical presentation of leprosy 🔗

The clinical manifestations of leprosy are diverse, primarily affecting the skin, peripheral nerves, upper respiratory tract mucosa, and eyes. The disease presents with characteristic cardinal signs that healthcare workers must recognize for early diagnosis.

Skin lesions 🔗

The most visible manifestation of leprosy involves skin changes. Patients typically present with hypopigmented (pale) or erythematous (reddish) skin patches that have a definite loss of sensation. These lesions may appear as flat patches, raised nodules, or diffuse thickening of the skin. In tuberculoid leprosy, there are limited skin lesions (1-5) that tend to be dry with well-defined borders. In lepromatous leprosy, skin involvement is more widespread, with numerous lesions, infiltrated nodules, and plaques affecting the face, ears, and hands.

Nerve damage 🔗

Peripheral nerve involvement is the hallmark of leprosy and the primary cause of disability. The bacteria target Schwann cells in peripheral nerves, leading to progressive nerve injury. This results in thickened, enlarged peripheral nerves that can often be palpated during clinical examination. The nerve damage causes sensory loss (numbness), motor weakness, and autonomic dysfunction. Commonly affected nerves include the ulnar, median, radial, common peroneal, and posterior tibial nerves.

The loss of protective sensation has serious consequences. Patients cannot feel pain from injuries, burns, or pressure, leading to repeated unnoticed trauma. Over time, this results in wounds, ulcers, secondary infections, and eventual tissue loss or resorption of digits-contrary to popular misconception, fingers and toes do not simply “fall off” but are lost through repeated injury and infection.

Classification of leprosy 🔗

For treatment purposes, leprosy cases are classified into two categories. Paucibacillary (PB) leprosy presents with 1-5 skin lesions without bacteria detected in skin smears, reflecting a strong cellular immune response. Multibacillary (MB) leprosy involves more than five skin lesions, nerve involvement, or detectable bacteria in skin smears, indicating a weaker immune response and higher bacterial load.

The burden of stigma 🔗

Beyond the physical manifestations, leprosy carries an immense social burden. The visible deformities and historical associations with the disease have led to profound stigma and discrimination that persist even today. Persons affected by leprosy face exclusion from education, employment, marriage, and social gatherings. According to a Law Commission of India report, several Indian laws historically allowed leprosy as grounds for divorce, perpetuating discrimination against affected individuals.

This stigma creates a dangerous cycle. Fear of social ostracism prevents individuals from seeking early medical care, allowing the disease to progress and increasing the risk of visible disabilities that further fuel discrimination. Community awareness programs must address not only the medical aspects but also these deeply ingrained social attitudes to encourage early self-reporting and treatment.

Multi-drug therapy: the cornerstone of treatment 🔗

The introduction of Multi-Drug Therapy (MDT) revolutionized leprosy treatment and control. First recommended by the WHO in the early 1980s, MDT combines three antibiotics: rifampicin, clofazimine, and dapsone. This combination effectively kills the bacteria and prevents the development of drug resistance that occurred with earlier single-drug treatments.

The treatment duration is six months for PB cases and twelve months for MB cases. Remarkably, patients become non-infectious after just the first dose of MDT, eliminating any justification for isolating affected individuals during treatment. The WHO provides MDT free of cost globally, with donations from pharmaceutical companies supporting this initiative.

In India, as of April 2025, the treatment protocol has been revised to align with WHO recommendations. A three-drug regimen is now used for both PB and MB cases, enhancing treatment uniformity across healthcare facilities.

National Leprosy Eradication Programme (NLEP) 🔗

India’s journey in combating leprosy began with the National Leprosy Control Programme launched in 1955, initially using dapsone monotherapy. With the advent of MDT, the programme was restructured as the National Leprosy Eradication Programme in 1983, shifting focus from mere control to elimination.

Achieving elimination status 🔗

Through sustained efforts, India achieved a historic milestone in December 2005-elimination of leprosy as a public health problem at the national level. This meant reducing prevalence to less than 1 case per 10,000 population, as defined by WHO standards. However, elimination at national level did not mean eradication. New cases continue to be detected, and some districts remain highly endemic.

Current strategies and goals 🔗

NLEP operates under the National Health Mission and provides free diagnostic and treatment services through all public health facilities. The programme’s current vision aligns with the goal of zero transmission, zero disability, and zero discrimination by 2027-three years ahead of the Sustainable Development Goals target of 2030.

Key strategies include early case detection through household contact surveys, involvement of Accredited Social Health Activists (ASHAs) in community-level detection, post-exposure prophylaxis using single-dose rifampicin for contacts, and intensive Information, Education, and Communication (IEC) activities. The programme has also established a digital platform called Nikusth 2.0 for real-time case tracking and surveillance.

Disability prevention and rehabilitation 🔗

NLEP places significant emphasis on Disability Prevention and Medical Rehabilitation (DPMR). Services include provision of Micro-Cellular Rubber (MCR) footwear to prevent plantar ulcers, physiotherapy services, corrective and reconstructive surgeries, and supply of aids like goggles for eye deformities. A welfare allowance is provided to patients undergoing reconstructive surgery to support their rehabilitation.

Community health nursing role 🔗

Community health nurses are essential to leprosy control efforts. Their responsibilities span multiple domains including case identification through active surveillance, administration of MDT and monitoring treatment compliance, health education to combat stigma and promote early reporting, contact tracing and prophylaxis administration, wound care and disability prevention counseling, and referral of complicated cases to higher centers.

Nurses working in endemic areas must maintain a high index of suspicion for leprosy, particularly when encountering patients with persistent skin patches accompanied by sensory loss. The challenges of treatment non-compliance require nurses to understand barriers such as loss of work hours for clinic visits, fear of social stigma, and drug side effects, and address them through supportive counseling and flexible service delivery.

Challenges in achieving eradication 🔗

Despite tremendous progress, complete eradication remains challenging. Hidden cases persist in communities due to stigma-driven delayed reporting. Child cases indicate ongoing transmission within communities. Some districts continue to have high prevalence rates. Additionally, the emergence of antimicrobial resistance, though currently limited, requires ongoing surveillance through sentinel sites established across the country.

The integration of leprosy services into general healthcare has improved accessibility but requires continuous training of healthcare staff who may have limited exposure to leprosy cases in low-endemic areas. The Global Appeal 2025 emphasized that logistical challenges and inconsistent funding continue to affect timely delivery of essential services in some regions.

The path forward 🔗

Achieving a leprosy-free India requires sustained commitment at all levels. This includes maintaining active surveillance and early case detection, ensuring uninterrupted MDT supply and treatment completion, intensifying contact tracing and prophylaxis administration, conducting regular awareness campaigns to reduce stigma, strengthening disability prevention services, and continuing research on diagnostics and treatment.

The National Strategic Plan and Roadmap for Leprosy 2023-2027 provides the framework for these efforts, emphasizing that medical management alone is insufficient-addressing social determinants and ensuring dignity for affected persons is equally crucial.

What do you think? How can community health nurses more effectively break the cycle of stigma that prevents early diagnosis and treatment of leprosy? What innovative approaches might help reach hidden cases in communities where fear of discrimination keeps affected individuals from seeking care?

References

1. https://www.ncbi.nlm.nih.gov/books/NBK559307/
2. https://www.who.int/news-room/fact-sheets/detail/leprosy
3. https://microbiologysociety.org/publication/past-issues/mycobacteria/article/mycobacterium-leprae-the-cause-of-leprosy.html
4. https://ruralindiaonline.org/en/library/resource/eliminating-discrimination-against-persons-affected-by-leprosy/
5. https://dghs.mohfw.gov.in/nlep.php
6. https://nhm.uk.gov.in/division/national-leprosy-eradication-programme-nlep/
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3137843/
8. https://sasakawaleprosyinitiative.org/latest-updates/initiative-news/5713/